Racura Oncology Ltd (ASX:RAC)
Australia · Delayed Price · Currency is AUD 2.020
-0.010 (-0.49%)
Sep 17, 2026, 4:10 PM AEST
Racura Oncology Company Description
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia.
It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers.
The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025.
Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Racura Oncology Ltd
| Country | Australia |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Daniel Tillett |
Contact Details
Address: Gateway, 1 Macquarie Place Sydney, NSW 2000 Australia | |
| Phone | 61 2 8051 3043 |
| Website | racuraoncology.com |
Stock Details
| Ticker Symbol | RAC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000RAC3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel Tillett | Chief Executive Officer, MD and Director |
| Dr. Peter Michael Smith Ph.D. | Executive Chairman |
| Brendan Brown | Chief Financial Officer |
| Dr. Sophia Moscovis | Vice President of Operations and Strategy |
| Dr. Jose L. Iglesias M.D. | Chief Medical Officer |
| Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |